Lipocine to Participate in the Cantor Neurology & Psychiatric Conference
Lipocine Inc. (NASDAQ: LPCN) announced its participation in the Cantor Neurology & Psychiatric Conference taking place on October 6-7, 2022 in San Francisco. The conference will be held at the Ritz Carlton Hotel, where investors can arrange 1x1 meetings. Lipocine focuses on developing products for CNS disorders through its proprietary Lip'ral platform, with candidates in development like LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy. The company aims to provide effective oral delivery options for significant medical needs.
- None.
- None.
SALT LAKE CITY, Sept. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules focused on treating CNS disorders, announced today that it will participate in the Cantor Neurology & Psychiatric Conference (October 6-7) in San Francisco.
Conference Details | |
Date: | October 6, 2022 |
Location: | Ritz Carlton Hotel, San Francisco |
Investors interested in arranging a 1x1 meeting at the conference should contact their Cantor representative.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop products for CNS disorders. Lipocine has candidates in development and candidates for which we are exploring partnering which target large addressable markets with significant unmet medical needs. Our candidates represent enablement of patient friendly oral delivery options for favorable benefit to risk profile.
Lipocine clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy and LPCN 1148, an oral prodrug of bioidentical testosterone targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering LPCN 1144, our candidate for treatment of non-cirrhotic NASH, LPCN 1148, LPCN 1107, our candidate for prevention of pre-term birth, and LPCN 1111, a once-a-day therapy candidate for testosterone replacement therapy (TRT). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
Forward-Looking Statements
This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, our strategic plans for developing products to treat CNS disorders, our ability to monetize non-core product candidates, the application of our Lip'ral platform in developing new treatments for CNS disorders, our product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates to treat CNS disorders, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-participate-in-the-cantor-neurology--psychiatric-conference-301634602.html
SOURCE Lipocine Inc.
FAQ
What event will Lipocine participate in on October 6-7, 2022?
Where is the Cantor Neurology & Psychiatric Conference being held?
What is Lipocine's focus at the conference?
What are some of Lipocine's candidates in development?
What technology does Lipocine use for its products?
